- Home
- LFST vs SRPT Comparison
LFST vs SRPT Comparison
Compare LFST & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | SRPT |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | LFST | SRPT |
|---|---|---|
| Price | $7.28 | $21.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 28 |
| Target Price | $8.83 | ★ $25.68 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,367,570,000.00 | ★ $2,413,715,000.00 |
| Revenue This Year | $15.83 | $13.99 |
| Revenue Next Year | $14.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.39 | ★ 47.15 |
| 52 Week Low | $3.74 | $10.42 |
| 52 Week High | $8.30 | $120.05 |
Technical Indicators
Market Signals| Indicator | LFST | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 47.33 |
| Support Level | $7.09 | $20.94 |
| Resistance Level | $7.48 | $23.00 |
| Average True Range (ATR) | 0.22 | 1.28 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 66.23 | 23.53 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.